The report forecasts the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.
Commenting on the report, an analyst from the research team said: A major trend which will boost market growth is the exploitation of novel therapeutic methods. The use of EPO has expanded to therapeutic areas other than for the treatment of anemia. For instance, recombinant EPO therapy is used to treat cardio-renal anemia syndrome. Use of EPO has shown an improvement in left and right ventricular systolic function in such patients with the reduction in cardiac remodeling, brain natriuretic peptide (BNP) levels, and hospitalization rate. Apart from this, with the discovery of EPO receptors in non-erythroid tissues, EPO has been investigated as a novel therapeutic agent in diseases and therapeutic conditions, including spinal cord injury, depression, diabetes, and as an immunomodulating agent.
According to the report, a key growth driver is the increase in CKD and dialysis patient population. An increase in the anemic population is expected to boost the market growth as EPO drugs are used as a treatment option for anemia. Anemia can be caused due to a number of diseases such as kidney disease, cancer, and HIV. In individuals with CKD, anemia develops due to the dysfunction of the kidneys. In this condition, the levels of EPO are low, which results in the development of anemia. Also, deficiency of iron, vitamin B12, and folic acid, which are essential for forming hemoglobin by RBCs, can result in anemia. The condition is aggravated in individuals undergoing dialysis; 80% of the individuals on dialysis are on EPO therapy to treat anemia
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- 3S Bio
- Shanghai Chemo
- Chengdu Di'ao
- NCPC Genetech
- Kyowa Hakko Kirin
- Shandong Kexing
- Ahua Pharmaceutical
- Dragon Pharma
- Huaxin High Biotechnology
- Kehua Bio-Engineering
- LG Life Sciences
- Shenzhen Sai Bao Er Bio-Pharmaceutical
- Shenyang Sunshine Pharmaceutical
- Uni-Bio Science Group
- Wanbang Biochemical Pharmaceuticals
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Erythropoietin: An overview
PART 06: Global erythropoietin market
PART 07: China: Country snapshot
PART 08: Opportunities for pharmaceutical vendors in China
PART 09: Biopharmaceutical market in China
PART 10: Market landscape
PART 11: Market segmentation by end-user
PART 12: Market segmentation by application
PART 13: Drug pricing and reimbursement in China
PART 14: Pipeline portfolio
PART 15: Market drivers
PART 16: Impact of drivers
PART 17: Market challenges
PART 18: Impact of drivers and challenges
PART 19: Market trends
PART 20: Vendor landscape
PART 21: Appendix
PART 22: About the Author
For more information visit http://www.researchandmarkets.com/research/wj2wfz/rhepo_market_in
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---china-rhepo-market-cagr-growth-of-1689-by-2020---trends-technologies--opportunities-report-2016-2020---key-vendors-3s-bio-sihuan-lg-life-sciences-300297180.html
SOURCE Research and Markets